Bipolar I Disorder Clinical Trial
Official title:
A Pilot Add-on Randomized, Placebo Controlled Intervention Trial of Cognitive Enhancement in Persons With Bipolar Disorder Using an Antioxidant and Advanced Glycation End (AGE) Product Inhibitor: L-Carnosine
Our hypothesis is that oral L-carnosine treatment (as compared with placebo) will enhance
cognitive abilities (specifically: measures of attention, executive function, working
memory, visuospatial ability and language) in persons with bipolar disorder. Secondarily, we
hypothesize there will be secondary improvements in positive, negative and mood symptoms
with L-carnosine treatment.
We aim to test these hypotheses by conducting a randomized, placebo controlled, add on
treatment trial of L-carnosine (added to existing antipsychotic treatment) on 48 recruited
subjects with DSM IV TR bipolar disorder for a period of 12 weeks. Measures of cognition,
and psychopathology will be utilized for evaluating primary and secondary outcomes, along
with safety assessments.
OBJECTIVE:
It is our hypothesis that L-carnosine treatment of persons with bipolar illness will improve
their cognitive outcomes, more specifically, measures of attention and executive function,
verbal and visuospatial memory and psychomotor performance, relative to placebo treatment.
We also hypothesize that L-carnosine treatment may secondarily improve any residual
affective symptoms.
RESEARCH PLAN:
We aim to test these hypotheses by conducting a randomized, placebo controlled, add on
treatment trial of L-carnosine (added to ongoing prescribed pharmacological treatment, for
example - lithium, anticonvulsants, antipsychotic agents and depressants) for a period of 12
weeks. Measures of cognition, and psychopathology will be utilized for evaluating primary
and secondary outcomes, along with safety assessments.
METHODS:
Up to 48 subjects with DSM IV TR bipolar I disorder will be recruited from Western
Psychiatric Institute and Clinic, Mayview State Hospital and Mon Yough Community Services,
Inc. using a 1:1 randomization, subjects who sign a informed consent document will be
randomized to receive L-carnosine or placebo.
It is expected that 12 of the 48 subjects may not meet inclusion/exclusion criteria, leaving
36 consenting adults (18 to 65 years) with DSM IV-TR Bipolar Disorder who will be assessed
for euthymia (Young Mania Rating Scale Score ≤ 10, Montgomery Asberg Depression Rating Scale
Score of ≤ 10) over a one month period (2 assessments) while receiving stable doses of their
current medications. They will also be assessed for cognitive dysfunction
(attention/executive function, immediate and declarative memory, and psychomotor
performance) using Cogtest - a proprietary neuropsychological library of 19 tests. These
subjects will be characterized for normal pre-morbid IQ, no ECT treatment in past 6 months,
no alcohol or substance dependence in past 6 months, mini-mental state score ≥ 24.
L-carnosine (or placebo) will be administered using random assignment at a dose of 500
mg/day, increasing each week by 500 mg to a dose of 2000 mg/day (twice daily schedule) in 4
weeks; as an adjunct to existing psychotropic medicines. The dose of 2000 mg (or less, i.e.
a minimum of 500 mg if tolerability is an issue) will be continued for 8 additional weeks.
L-carnosine is not known to have interactions with psychotropic drugs but mood-stabilizer
levels will be monitored.
Standard psychopathology rating scales will be administered to evaluate secondary aims such
as impact on residual symptoms of bipolar disorder. Safety will be assessed by tailing a
careful medical history and physical examination at screening and evaluating results of
laboratory measures. Any adverse effects will be assessed by asking questions at each visit,
and if required bring subjects in for assessments outside the scheduled visits, and by
telephone contact in between longer scheduled visits.
SIGNIFICANCE:
Cognitive dysfunction can seriously hinder improved functional outcomes in persons with
schizophrenia or bipolar disorder. If this short term intervention with L-carnosine shows
promise, more definitive studies using adequate powered sample sizes, and of longer duration
can be conducted. If improvements in cognitive problems are linked to improved functional
outcomes using such supplemental treatments, an important therapeutic milestone in bipolar
disorder will have been achieved.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Withdrawn |
NCT01495156 -
Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania
|
Phase 4 | |
Completed |
NCT00982020 -
Study in Adolescents With Schizophrenia or Bipolar Disorder
|
Phase 4 | |
Completed |
NCT00746343 -
Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study
|
N/A | |
Completed |
NCT03257865 -
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder
|
Phase 3 | |
Completed |
NCT03259555 -
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
|
Phase 3 | |
Not yet recruiting |
NCT06433635 -
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
|
Phase 4 | |
Completed |
NCT04127058 -
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
|
Phase 1 | |
Recruiting |
NCT05977023 -
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
|
Phase 2 | |
Recruiting |
NCT05340686 -
Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression
|
N/A | |
Completed |
NCT03287869 -
A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
|
Phase 3 | |
Enrolling by invitation |
NCT04987229 -
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
|
Phase 3 | |
Completed |
NCT00761761 -
Sensoril(Ashwaganhda)for Bipolar Disorder
|
Phase 3 | |
Completed |
NCT00232414 -
A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder
|
Phase 3 | |
Completed |
NCT03292848 -
Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders
|
Phase 1 | |
Active, not recruiting |
NCT04561622 -
Emotional Proactive Processing in Bipolar Disorder
|
||
Recruiting |
NCT03943537 -
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
|
Phase 2 | |
Completed |
NCT03334721 -
Gabapentin for Bipolar & Cannabis Use Disorders
|
Phase 2 | |
Active, not recruiting |
NCT05658510 -
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
|
Phase 3 | |
Completed |
NCT00958633 -
Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.
|
Phase 3 |